Abstracts tagged "spondyloarthritis"

Abstract Number: 0410 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Marina Magrey¹, Atul Deodhar², Philip J Mease³, Victoria Navarro-Compán⁴, Sofia Ramiro⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Vanessa Taieb⁹, Michael Frank Mørup¹⁰, Marga Oortgiesen¹¹ and Jonathan Kay¹², ¹Case Western Reserve University, University Hospitals, Richfield, OH, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Colombes, France, ¹⁰UCB Pharma, Copenhagen, Denmark, ¹¹UCB Pharma, Raleigh, NC, ¹²Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Examine the association between achieving increasingly stringent clinical response criteria and lower levels of disease activity, and improvements in physical function and health-related quality…
Abstract Number: 0731 • ACR Convergence 2022
Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
Diego Benavent¹, Luis Fernández-Luque², María Sanz-Jardón¹, Victoria Navarro-Compán³, Pau Altur², Enrique Calvo⁴, Leticia Lojo⁴, Alejandro Balsa⁵ and Chamaida Plasencia-Rodriguez⁶, ¹La Paz University Hospital, Madrid, Spain, ²AdheraHealth Inc, Palo Alto, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario Infanta Leonor, Madrid, Spain, ⁵Hospital La Paz Institute for Health Research, Madrid, Spain, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that is limited by the capacity of healthcare professionals. The implementation of innovative…
Abstract Number: 1027 • ACR Convergence 2022
Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Monique Reijnierse⁴, Juergen Braun⁵, Xenofon Baraliakos⁶, floris van Gaalen⁴ and Sofia Ramiro⁴, ¹Leiden University Medical Center, Coimbra, Portugal, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: In radiographic axial Spondyloarthritis (r-axSpA), low dose Computed Tomography (ldCT) Hounsfield Units (HU) were shown to cross-sectionally reliably assess bone density at each vertebra…
Abstract Number: 1244 • ACR Convergence 2022
Incidence of Radiographic Spinal Damage in Psoriatic Arthritis Patients Compared to Spondyloarthritis Patients: Which Patients Are More Affected?
Manouk de Hooge¹, Alla Alexeevna Ishchenko², Ann-Sophie Kathleen De Craemer³, Serge Steinfeld⁴, Adrien NZEUSSEU TOUKAP⁵, Filip Van den bosch⁶, Dirk Elewaut⁷, Rik Lories⁸ and Kurt de Vlam⁹, ¹Ghent University Hospital, Luxembourg, Luxembourg, ²University Hospitals Leuven, Sint-Stevens-Woluwe, Belgium, ³Ghent University Hospital, Gent, Belgium, ⁴Clinique Saint-Jean, Brussels, Belgium, ⁵Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁶Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁷Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁸KU Leuven, Leuven, Belgium, ⁹University Hospitals Leuven, Leuven, Belgium
Background/Purpose: There is an ongoing debate on axial involvement in psoriatic arthritis (PsA) patients. This study reports the baseline radiographic spinal damage in PsA and…
Abstract Number: 1515 • ACR Convergence 2022
Assessing the Difference Between Radiographic Axial Spondylorthritis and Non-radiographic Axial Spondylorthritis in a Two-center Descriptive Study with Mexican Patients: The Influence of Clinical, Demographic, Laboratory and Clinimetric Features
John Londono¹, Gustavo Rodriguez-Salas², Igor Rueda-Cardenas³, Ana Maria Santos¹, Marta Mantilla¹, Juan Camilo Santacruz², Cesar Pachecho⁴, Gilberto Vargas-Alarcon⁵ and Ruben Burgos vargas⁶, ¹Spondyloarthropathies study group - Universidad de La Sabana - Hospital Militar Central, Bogotá, Colombia, ²Spondyloathropathies study group Universidad de La Sabana Hospital Militar Central, Bogotá, Colombia, ³Spondyloarthropathies study group - Universidad de LA Sabana - Hospital Militar Central, Colombia, Colombia, ⁴Universidad Autónoma de chihuahua, Chihuahua, Mexico, ⁵Insituto Nacional de Cardiología Ignacio Chavez, Ciudad de México, Mexico, ⁶hospital general de mexico, Ciudad de México, Mexico
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases that have some key features in common. According to ASAS, this condition is classified into…
Abstract Number: 2132 • ACR Convergence 2022
Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
Roy Fleischmann¹, Diamant Thaci², Melinda Gooderham³, Bruce Strober⁴, Neil J. Korman⁵, Subhashis Banerjee⁶, Tom Lehman⁶, Miroslawa Nowak⁶, Antoine Sreih⁷, Akimichi Morita⁸ and Philip J Mease⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ³SKiN Centre for Dermatology, Queen’s University, Probity Medical Research, Peterborough, Canada, ⁴Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, ⁵Case Western Reserve University and University Hospitals, Cleveland, OH, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Philadelphia, PA, ⁸Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action distinct from Janus kinase (JAK)…
Abstract Number: 0376 • ACR Convergence 2022
The Socioeconomic Profile of Patients with Radiographic Axial Spondyloarthritis Is Associated with the Severity of the Disease and with the Permanent Disability. a Cluster Analysis in a National Spanish Registry
Clementina Lopez-Medina¹, Desiree Ruiz-Vilchez², Maria Angeles Puche Larrubia³, lourdes Ladehesa-Pineda⁴, Pilar Font⁵ and Eduardo Collantes⁵, ¹Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ²Reina Sofia University Hospital, Cordoba, Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ⁴Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain
Background/Purpose: Previous studies have demonstrated that male gender and higher level of education are independently associated with a lower hazard of sick leave in patients…
Abstract Number: 0411 • ACR Convergence 2022
Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
Désirée van der Heijde¹, Xenofon Baraliakos², Maxime Dougados³, Matthew Brown⁴, Denis Poddubnyy⁵, Filip Van den bosch⁶, Nigil Haroon⁷, Huji Xu⁸, Tetsuya Tomita⁹, Lianne Gensler¹⁰, Marga Oortgiesen¹¹, Carmen Fleurinck¹², Natasha de Peyrecave¹³, Thomas Vaux¹⁴, Alexander Marten¹⁵ and Atul Deodhar¹⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁴Genomics England, London, United Kingdom, ⁵Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁷Schroeder Arthritis Institute, University Health Network; University of Toronto, Toronto, ON, Canada, ⁸Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China, ⁹Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Osaka, Japan, Suita Osaka, Japan, ¹⁰Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ¹¹UCB Pharma, Raleigh, NC, ¹²UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ¹³UCB Pharma, Brussels, Belgium, ¹⁴UCB Pharma, Slough, United Kingdom, ¹⁵UCB Pharma, Monheim am Rhein, Germany, ¹⁶Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid and…
Abstract Number: 0774 • ACR Convergence 2022
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
Marthe K. Brun¹, Kristin Hammersbøen Bjørlykke², Marte Kathrine Viken³, Grete-Elisabeth Stenvik¹, Rolf Klaasen³, Johanna Elin Gehin³, David Warren³, Joe Sexton¹, Espen Haavardsholm¹, Jørgen Jahnsen², Benedicte Alexandra Lie³, Nils Bolstad³, Kristin Kaasen Jørgensen², Guro Løvik Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway
Background/Purpose: Immunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been…
Abstract Number: 1034 • ACR Convergence 2022
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Kathryn Starzyk, Pam Kumparatana and roger Meng, OM¹, Inc., Boston, MA
Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…
Abstract Number: 1248 • ACR Convergence 2022
A Retrospective Chart Review Examining How a Change in MRI Protocol Could Affect the Diagnosis of Axial Spondyloarthritis
Alexa Kouroukis¹, Manisha Mulgund², Leilani Famorca³, Pauline Boulos¹ and Viktoria Pavlova⁴, ¹McMaster University, Hamilton, ON, Canada, ²Trillium Health Partners, Ancaster, ON, Canada, ³McMaster University, Milton, ON, Canada, ⁴McMaster University, Ancaster, ON, Canada
Background/Purpose: St. Joseph's Healthcare Hamilton (SJHH) recently changed their MRI-axial spondyloarthritis (axSpA) protocol, used to diagnose patients with axSpA, from an MRI of the spine…
Abstract Number: 1516 • ACR Convergence 2022
How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
Federico Fattorini¹, Cosimo Cigolini², Gabriele Marchetti³, Andrea Delle Sedie⁴, Linda Carli⁵ and Marta Mosca⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ³University of Pisa, Pisa, Toscana, Italy, ⁴University of Pisa, Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, Italy
Background/Purpose: Spondyloarthropathies (SpA) may compromise the working ability (WA) of patients, often affected by the disease during their productive life. The Work Productivity and Activity…
Abstract Number: 2133 • ACR Convergence 2022
Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
Oliver FitzGerald¹, Dafna Gladman², Philip J Mease³, Christopher Ritchlin⁴, Josef Smolen⁵, Lu Gao⁶, Sarah Hu⁶, Miroslawa Nowak⁶, Subhashis Banerjee⁶ and Ian M. Catlett⁶, ¹Conway Institute, University College Dublin, Dublin, Ireland, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Medical University of Vienna, Vienna, Austria, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective TYK2 inhibitor with a unique allosteric mechanism of action that has demonstrated efficacy in patients with psoriasis1…
Abstract Number: 0378 • ACR Convergence 2022
Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics
Atul Deodhar¹, Sonam Kiwalkar², Kim Phung Nguyen³, Rose Quinn³, David Perham⁴, William Malatestinic⁵, Rebecca Bolce⁶, Theresa Hunter⁵, Pragya Khurana⁷ and Shireesh Bhalerao⁴, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Washington State University, Portland, OR, ³Oregon Health & Science University, Portland, OR, ⁴Private Practice, Portland, OR, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Cincinnati, OH, ⁷ICON plc, Blue Bell, PA
Background/Purpose: Patients with chronic back pain (CBP; back, buttock, or hip pain ≥ 3 months) where the underlying cause may be axSpA are usually first…
Abstract Number: 0412 • ACR Convergence 2022
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Lianne Gensler³, Jonathan Kay⁴, Victoria Navarro-Compán⁵, Christine de la Loge⁶, Alicia Ellis⁷, Carmen Fleurinck⁸, Marga Oortgiesen⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Colombes, France, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impacts patients' (pts) physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].